Risk factors of carbapenem-resistant Klebsiella pneumoniae infection in tumor patients
10.3760/cma.j.issn.1674-2397.2023.06.006
- VernacularTitle:肿瘤患者碳青霉烯类耐药肺炎克雷伯菌感染的危险因素分析
- Author:
Huiping ZHANG
1
;
Xiaofan HE
;
Li TANG
Author Information
1. 杭州市肿瘤医院检验科，杭州 310002
- Keywords:
Klebsiella pneumoniae;
Carbapenems;
Drug resistance;
Tumor patient;
Risk factor
- From:
Chinese Journal of Clinical Infectious Diseases
2023;16(6):452-456
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the risk factors of carbapenem-resistant Klebsiella pneumoniae（CRKP）infection in tumor patients. Methods:The clinical data of hospitalized tumor patients with Klebsiella pneumoniae（KP）infection admitted in Hangzhou Cancer Hospital during January 2021 to December 2022 were retrospectively analyzed. Patients were divided into CRKP group（ n=37）and carbapenem-sensitive Klebsiella pneumoniae（CSKP）group（ n=142）according to drug sensitivity. The risk factors of CRKP infection were analyzed by univariate and multivariate Logistic regression. Results:Univariate analysis showed that cardiovascular disease（ χ2=4.554， P=0.033），carbapenem use ≥7 days（ χ2=53.483， P<0.001）and hospital stay >7 days（ χ2=3.871， P=0.049）were significantly associated with CRKP infection in tumor patients. Multivariate Logistic analysis showed that carbapenem therapy for ≥7 days（ OR=18.280，95% CI 6.533-51.147， P<0.001）was an independent risk factor for CRKP infection in tumor patients. Conclusion:Tumor patients with long-term use of carbapenems are prone to CRKP infection.
